185 related articles for article (PubMed ID: 16485142)
1. Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis.
Grabowski P; Sturm I; Schelwies K; Maaser K; Buhr HJ; Dörken B; Zeitz M; Daniel PT; Scherübl H
Int J Colorectal Dis; 2006 Apr; 21(3):221-30. PubMed ID: 16485142
[TBL] [Abstract][Full Text] [Related]
2. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors.
Schelwies K; Sturm I; Grabowski P; Scherübl H; Schindler I; Hermann S; Stein H; Buhr HJ; Riecken EO; Zeitz M; Dörken B; Daniel PT
Int J Cancer; 2002 Jun; 99(4):589-96. PubMed ID: 11992551
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.
Sturm I; Köhne CH; Wolff G; Petrowsky H; Hillebrand T; Hauptmann S; Lorenz M; Dörken B; Daniel PT
J Clin Oncol; 1999 May; 17(5):1364-74. PubMed ID: 10334520
[TBL] [Abstract][Full Text] [Related]
4. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX.
Nehls O; Okech T; Hsieh CJ; Enzinger T; Sarbia M; Borchard F; Gruenagel HH; Gaco V; Hass HG; Arkenau HT; Hartmann JT; Porschen R; Gregor M; Klump B
Br J Cancer; 2007 May; 96(9):1409-18. PubMed ID: 17426704
[TBL] [Abstract][Full Text] [Related]
5. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma.
Giatromanolaki A; Stathopoulos GP; Tsiompanou E; Papadimitriou C; Georgoulias V; Gatter KC; Harris AL; Koukourakis MI
Cancer; 1999 Oct; 86(8):1421-30. PubMed ID: 10526268
[TBL] [Abstract][Full Text] [Related]
6. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
[TBL] [Abstract][Full Text] [Related]
8. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis.
Sturm I; Petrowsky H; Volz R; Lorenz M; Radetzki S; Hillebrand T; Wolff G; Hauptmann S; Dörken B; Daniel PT
J Clin Oncol; 2001 Apr; 19(8):2272-81. PubMed ID: 11304781
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer.
Grabowski P; Schindler I; Anagnostopoulos I; Foss HD; Riecken EO; Mansmann U; Stein H; Berger G; Buhr HJ; Scherübl H
Eur J Gastroenterol Hepatol; 2001 Apr; 13(4):405-11. PubMed ID: 11338071
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of multimarker analysis in stage III colorectal cancer: one step forward towards an individualized therapy decision.
Grabowski P; Maaser K; Hanski C; Stein H; Sturm I; Hopfenmüller W; Dörken B; Buhr HJ; Zeitz M; Scherübl H
Onkologie; 2005 Aug; 28(8-9):399-403. PubMed ID: 16160402
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.
Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A
Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036
[TBL] [Abstract][Full Text] [Related]
13. Expression of SIALYL-Le(x) antigen defined by MAb AM-3 is an independent prognostic marker in colorectal carcinoma patients.
Grabowski P; Mann B; Mansmann U; Lövin N; Foss HD; Berger G; Scherübl H; Riecken EO; Buhr HJ; Hanski C
Int J Cancer; 2000 Oct; 88(2):281-6. PubMed ID: 11004681
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of p53 messenger ribonucleic acid expression in patients after curative resection for stage I to III colorectal cancer: association with colon cancer stem cell markers.
Huh JW; Kim HR; Kim YJ
J Am Coll Surg; 2013 Jun; 216(6):1063-9. PubMed ID: 23571142
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
16. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
17. Is neuroendocrine differentiation a prognostic factor in poorly differentiated colorectal cancer?
Chen Y; Liu F; Meng Q; Ma S
World J Surg Oncol; 2017 Mar; 15(1):71. PubMed ID: 28351413
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the peripheral benzodiazepine receptor is a relevant prognostic factor in stage III colorectal cancer.
Maaser K; Grabowski P; Sutter AP; Höpfner M; Foss HD; Stein H; Berger G; Gavish M; Zeitz M; Scherübl H
Clin Cancer Res; 2002 Oct; 8(10):3205-9. PubMed ID: 12374690
[TBL] [Abstract][Full Text] [Related]
19. Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis.
Güner D; Sturm I; Hemmati P; Hermann S; Hauptmann S; Wurm R; Budach V; Dörken B; Lorenz M; Daniel PT
Int J Cancer; 2003 Feb; 103(4):445-54. PubMed ID: 12478659
[TBL] [Abstract][Full Text] [Related]
20. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
